15627759

Source:http://linkedlifedata.com/resource/pubmed/id/15627759

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002395, umls-concept:C0017431, umls-concept:C0030705, umls-concept:C0039485, umls-concept:C0087111, umls-concept:C0205098, umls-concept:C0333641, umls-concept:C0649350, umls-concept:C0681842, umls-concept:C1412481, umls-concept:C1516691
pubmed:issue	2-3
pubmed:dateCreated	2005-2-15
pubmed:abstractText	Only a subgroup of subjects with probable AD shows cognitive improvement after treatment with cholinesterase inhibitors.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9705200
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Apolipoprotein E4, http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E, http://linkedlifedata.com/resource/pubmed/chemical/Cholinesterase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents, http://linkedlifedata.com/resource/pubmed/chemical/Phenylcarbamates, http://linkedlifedata.com/resource/pubmed/chemical/rivastigmine
pubmed:status	MEDLINE
pubmed:issn	1420-8008
pubmed:author	pubmed-author:Dutch ENA-NL-01 Study Group, pubmed-author:PelgrimEstherE, pubmed-author:ScheltensPhilipP, pubmed-author:VerheyFrans R JFR, pubmed-author:VisserPieter JellePJ
pubmed:issnType	Print
pubmed:volume	19
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	126-33
pubmed:dateRevised	2008-3-24
pubmed:meshHeading	pubmed-meshheading:15627759-Aged, pubmed-meshheading:15627759-Aged, 80 and over, pubmed-meshheading:15627759-Alzheimer Disease, pubmed-meshheading:15627759-Apolipoprotein E4, pubmed-meshheading:15627759-Apolipoproteins E, pubmed-meshheading:15627759-Atrophy, pubmed-meshheading:15627759-Cholinesterase Inhibitors, pubmed-meshheading:15627759-Dose-Response Relationship, Drug, pubmed-meshheading:15627759-Drug Administration Schedule, pubmed-meshheading:15627759-Female, pubmed-meshheading:15627759-Follow-Up Studies, pubmed-meshheading:15627759-Genetics, pubmed-meshheading:15627759-Genotype, pubmed-meshheading:15627759-Humans, pubmed-meshheading:15627759-Magnetic Resonance Imaging, pubmed-meshheading:15627759-Male, pubmed-meshheading:15627759-Mental Status Schedule, pubmed-meshheading:15627759-Netherlands, pubmed-meshheading:15627759-Neuroprotective Agents, pubmed-meshheading:15627759-Phenylcarbamates, pubmed-meshheading:15627759-Prognosis, pubmed-meshheading:15627759-Psychometrics, pubmed-meshheading:15627759-Temporal Lobe, pubmed-meshheading:15627759-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
pubmed:affiliation	Department of Neurology, Alzheimer Centre, VU Medisch Centrum, Amsterdam, The Netherlands. pj.visser@vumc.nl
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't